Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP62303.RAXdlayZhQa5MhCuoGzuR70DY9CrwhprNhdZZke2vsMwo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP62303.RAXdlayZhQa5MhCuoGzuR70DY9CrwhprNhdZZke2vsMwo130_assertion type Assertion NP62303.RAXdlayZhQa5MhCuoGzuR70DY9CrwhprNhdZZke2vsMwo130_head.
- NP62303.RAXdlayZhQa5MhCuoGzuR70DY9CrwhprNhdZZke2vsMwo130_assertion description "[ It is concluded that genotyping for ABCB1 1236C>T may be one of the factors assisting with dose optimization of irinotecan chemotherapy in cancer patients. Additional investigation is required to confirm these findings in a larger population and to assess relationships between irinotecan disposition and the rare variant genotypes, especially in other ethnic groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP62303.RAXdlayZhQa5MhCuoGzuR70DY9CrwhprNhdZZke2vsMwo130_provenance.
- NP62303.RAXdlayZhQa5MhCuoGzuR70DY9CrwhprNhdZZke2vsMwo130_assertion evidence source_evidence_literature NP62303.RAXdlayZhQa5MhCuoGzuR70DY9CrwhprNhdZZke2vsMwo130_provenance.
- NP62303.RAXdlayZhQa5MhCuoGzuR70DY9CrwhprNhdZZke2vsMwo130_assertion SIO_000772 12960109 NP62303.RAXdlayZhQa5MhCuoGzuR70DY9CrwhprNhdZZke2vsMwo130_provenance.
- NP62303.RAXdlayZhQa5MhCuoGzuR70DY9CrwhprNhdZZke2vsMwo130_assertion wasDerivedFrom gad-20130706 NP62303.RAXdlayZhQa5MhCuoGzuR70DY9CrwhprNhdZZke2vsMwo130_provenance.
- NP62303.RAXdlayZhQa5MhCuoGzuR70DY9CrwhprNhdZZke2vsMwo130_assertion wasGeneratedBy ECO_0000203 NP62303.RAXdlayZhQa5MhCuoGzuR70DY9CrwhprNhdZZke2vsMwo130_provenance.